Additive effects of combined blockade of AT1 receptor and HMG-CoA reductase on left ventricular remodeling in infarcted rats

Tsung-Ming Lee, Mei Shu Lin, Tsai Fwu Chou, Nen Chung Chang

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Both angiotensin receptor antagonists and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have been shown to attenuate cardiomyocyte hypertrophy after myocardial infarction. Whether combination treatment may be superior to either drug alone on cardiomyocyte hypertrophy remains unclear. After ligation of the left anterior descending artery, rats were randomized to both, one, or neither of the angiotensin receptor antagonists olmesartan (0.01, 0.1, 1, and 2 mg·kg-1·day -1) and HMG-CoA reductase inhibitor pravastatin (5 mg·kg -1·day-1) for 4 wk. Each drug, when given alone, decreased cardiomyocyte sizes isolated by enzymatic dissociation at the border zone when compared with vehicles. However, compared with either drug alone, combined olmesartan and pravastatin prevent cardiomyocyte hypertrophy to a larger extent, which was further confirmed by downregulation of the left ventricular atrial natriuretic peptide mRNA. The myocardial endothelin-1 levels at the border zone were 6.5-fold higher (P

Original languageEnglish
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume291
Issue number3
DOIs
Publication statusPublished - 2006

Fingerprint

Ventricular Remodeling
Cardiac Myocytes
Oxidoreductases
Hypertrophy
Pravastatin
Angiotensin Receptor Antagonists
Pharmaceutical Preparations
Atrial Natriuretic Factor
Endothelin-1
Ligation
Down-Regulation
Arteries
Myocardial Infarction
Messenger RNA
3-hydroxy-3-methylglutaryl-coenzyme A
olmesartan

Keywords

  • 3-hydroxy-3- methylgultaryl coenzyme A
  • Arrhythmias
  • Hypertrophy
  • Myocardial infarction
  • Myocytes

ASJC Scopus subject areas

  • Physiology

Cite this

@article{baf34ac1e4934d58811e2bdd17097ae5,
title = "Additive effects of combined blockade of AT1 receptor and HMG-CoA reductase on left ventricular remodeling in infarcted rats",
abstract = "Both angiotensin receptor antagonists and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have been shown to attenuate cardiomyocyte hypertrophy after myocardial infarction. Whether combination treatment may be superior to either drug alone on cardiomyocyte hypertrophy remains unclear. After ligation of the left anterior descending artery, rats were randomized to both, one, or neither of the angiotensin receptor antagonists olmesartan (0.01, 0.1, 1, and 2 mg·kg-1·day -1) and HMG-CoA reductase inhibitor pravastatin (5 mg·kg -1·day-1) for 4 wk. Each drug, when given alone, decreased cardiomyocyte sizes isolated by enzymatic dissociation at the border zone when compared with vehicles. However, compared with either drug alone, combined olmesartan and pravastatin prevent cardiomyocyte hypertrophy to a larger extent, which was further confirmed by downregulation of the left ventricular atrial natriuretic peptide mRNA. The myocardial endothelin-1 levels at the border zone were 6.5-fold higher (P",
keywords = "3-hydroxy-3- methylgultaryl coenzyme A, Arrhythmias, Hypertrophy, Myocardial infarction, Myocytes",
author = "Tsung-Ming Lee and Lin, {Mei Shu} and Chou, {Tsai Fwu} and Chang, {Nen Chung}",
year = "2006",
doi = "10.1152/ajpheart.00792.2005",
language = "English",
volume = "291",
journal = "American Journal of Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "3",

}

TY - JOUR

T1 - Additive effects of combined blockade of AT1 receptor and HMG-CoA reductase on left ventricular remodeling in infarcted rats

AU - Lee, Tsung-Ming

AU - Lin, Mei Shu

AU - Chou, Tsai Fwu

AU - Chang, Nen Chung

PY - 2006

Y1 - 2006

N2 - Both angiotensin receptor antagonists and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have been shown to attenuate cardiomyocyte hypertrophy after myocardial infarction. Whether combination treatment may be superior to either drug alone on cardiomyocyte hypertrophy remains unclear. After ligation of the left anterior descending artery, rats were randomized to both, one, or neither of the angiotensin receptor antagonists olmesartan (0.01, 0.1, 1, and 2 mg·kg-1·day -1) and HMG-CoA reductase inhibitor pravastatin (5 mg·kg -1·day-1) for 4 wk. Each drug, when given alone, decreased cardiomyocyte sizes isolated by enzymatic dissociation at the border zone when compared with vehicles. However, compared with either drug alone, combined olmesartan and pravastatin prevent cardiomyocyte hypertrophy to a larger extent, which was further confirmed by downregulation of the left ventricular atrial natriuretic peptide mRNA. The myocardial endothelin-1 levels at the border zone were 6.5-fold higher (P

AB - Both angiotensin receptor antagonists and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have been shown to attenuate cardiomyocyte hypertrophy after myocardial infarction. Whether combination treatment may be superior to either drug alone on cardiomyocyte hypertrophy remains unclear. After ligation of the left anterior descending artery, rats were randomized to both, one, or neither of the angiotensin receptor antagonists olmesartan (0.01, 0.1, 1, and 2 mg·kg-1·day -1) and HMG-CoA reductase inhibitor pravastatin (5 mg·kg -1·day-1) for 4 wk. Each drug, when given alone, decreased cardiomyocyte sizes isolated by enzymatic dissociation at the border zone when compared with vehicles. However, compared with either drug alone, combined olmesartan and pravastatin prevent cardiomyocyte hypertrophy to a larger extent, which was further confirmed by downregulation of the left ventricular atrial natriuretic peptide mRNA. The myocardial endothelin-1 levels at the border zone were 6.5-fold higher (P

KW - 3-hydroxy-3- methylgultaryl coenzyme A

KW - Arrhythmias

KW - Hypertrophy

KW - Myocardial infarction

KW - Myocytes

UR - http://www.scopus.com/inward/record.url?scp=33748416629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748416629&partnerID=8YFLogxK

U2 - 10.1152/ajpheart.00792.2005

DO - 10.1152/ajpheart.00792.2005

M3 - Article

VL - 291

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6135

IS - 3

ER -